The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBrooks Macdonald Regulatory News (BRK)

Share Price Information for Brooks Macdonald (BRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,020.00
Bid: 1,995.00
Ask: 2,030.00
Change: 62.50 (3.21%)
Spread: 35.00 (1.754%)
Open: 2,040.00
High: 2,050.00
Low: 1,980.00
Prev. Close: 1,950.00
BRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director appointment

16 Feb 2023 07:00

RNS Number : 0700Q
Brooks Macdonald Group PLC
16 February 2023
 

16 February 2023

 

BROOKS MACDONALD GROUP PLC

 

Director appointment

 

Brooks Macdonald Group plc ("The Group", "Brooks Macdonald") is pleased to announce the appointment of James Rawlingson as Non-Executive Director effective 2 March 2023. James will in due course assume the role of Chairman of the Audit Committee, subject to regulatory approval.

 

James currently serves as Chairman of the Audit and Risk Committee at Citibank UK, Chairman of the Audit and Risk Assurance Committee at the Foreign Office's executive agency Wilton Park, and Chairman of the Board at Novai Ltd. In his executive career James has held senior positions at Coutts, UBS Wealth, Charles Stanley plc and Arix Bioscience plc.

 

Commenting on the appointment, Acting Chairman Richard Price said: "I am delighted that James is joining the Board. James has had an extensive career and his sector experience will provide valuable insight as the Company continues towards its strategic goals."

 

AIM disclosures

 

During the five years immediately preceding the date of this announcement, James Hedley Rawlingson, who is 55 years old, held the following directorships:

 

Current

 

Citibank UK Limited

Wilton Park (an Arm's Length Body of the British Foreign, Commonwealth & Development Office)

Novai Limited

 

Previous

 

Next Gen PPE limited

Arix Bioscience Holdings Limited

Arix Bioscience plc

Arthurian Life Sciences GP Limited

Als SPV Limited

Arix Capital Management Limited

Arthurian Life Sciences SPV GP Limited

 

There is no further information to be disclosed pursuant to Schedule Two Part (g) of the AIM Rules for Companies.

 

Enquiries to:

Brooks Macdonald Group plc

Andrew Shepherd, CEO

www.brooksmacdonald.com

020 7927 4816

 

Peel Hunt LLP (Nominated Adviser and Broker)

Paul Shackleton / Andrew Buchanan / John Welch

020 7418 8900

 

FTI Consulting

Laura Ewart / Katherine Bell

brooksmacdonald@fticonsulting.com

07711 387 085 / 07976 870 961

 

Notes to editors

 

Brooks Macdonald Group plc, through its various subsidiaries, provides leading investment management services in the UK and internationally. The Group, which was founded in 1991 and began trading on AIM in 2005, had discretionary Funds under Management of £16.2 billion as at 31 December 2022.

 

Brooks Macdonald offers a range of investment management services to private high net worth individuals, pension funds, institutions, charities and trusts. The Group also provides financial planning as well as international investment management, and acts as fund manager to a range of onshore and international funds.

 

The Group has fifteen offices across the UK and Crown Dependencies including London, Birmingham, Cheltenham, East Anglia, Exeter, Leeds, Manchester, Nuneaton, Southampton, Tunbridge Wells, Scotland, Wales, Jersey, Guernsey and Isle of Man.

 

LEI: 213800WRDF8LB8MIEX37

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUVSWROAUUAAR
Date   Source Headline
31st Mar 202310:47 amRNSForm 8.3 - US Solar Fund plc
30th Mar 202312:59 pmRNSForm 8.3 - US Solar Fund plc
29th Mar 202310:57 amRNSForm 8.3 - US Solar Fund plc
28th Mar 202311:13 amRNSForm 8.3 - US Solar Fund plc
27th Mar 202310:57 amRNSForm 8.3 - US Solar Fund plc
23rd Mar 202310:12 amRNSForm 8.3 - US Solar Fund plc
20th Mar 202311:43 amRNSForm 8.3 - US Solar Fund plc
15th Mar 202310:44 amRNSForm 8.3 - US Solar Fund plc
14th Mar 202310:34 amRNSForm 8.3 - US Solar Fund plc
6th Mar 202310:17 amRNSForm 8.3 - US Solar Fund plc
3rd Mar 202310:39 amRNSForm 8.3 - US Solar Fund plc
2nd Mar 20237:00 amRNSHalf-year results for the 6 months ended 31/12/22
1st Mar 202312:39 pmRNSForm 8.3 - US Solar Fund plc
1st Mar 20237:00 amRNSTotal Voting Rights
22nd Feb 202311:17 amRNSForm 8.3 - US Solar Fund plc
17th Feb 202310:34 amRNSForm 8.3 - US Solar Fund plc
16th Feb 20237:00 amRNSDirector appointment
15th Feb 202310:48 amRNSForm 8.3 - US Solar Fund PLC
14th Feb 202310:56 amRNSForm 8.3 - US Solar Fund PLC
14th Feb 20238:00 amRNSNotice of Interim Results Investor Presentation
13th Feb 202310:26 amRNSForm 8.3 - US Solar Fund plc
10th Feb 202312:54 pmRNSForm 8.3 - US Solar Fund plc
7th Feb 202312:17 pmRNSForm 8.3 - US Solar Fund plc
7th Feb 20237:00 amRNSDirectorate Change
2nd Feb 202310:50 amRNSForm 8.3 - US Solar Fund PLc
1st Feb 20237:00 amRNSTotal Voting Rights
25th Jan 20237:00 amRNSIssue of equity to vendors re Integrity Wealth
24th Jan 202311:32 amRNSForm 8.3 - US Solar Fund PLC
19th Jan 202311:03 amRNSDirectorate Change
17th Jan 202310:49 amRNSForm 8.3 - US Solar Fund PLC
16th Jan 202310:09 amRNSForm 8.3 - US Solar Fund plc
12th Jan 202310:18 amRNSForm 8.3 - US Solar Fund plc
12th Jan 20237:00 amRNSQuarterly Announcement of Funds under Management
9th Jan 202310:31 amRNSForm 8.3 - US Solar Fund plc
3rd Jan 20237:00 amRNSTotal Voting Rights
29th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
14th Dec 20223:11 pmRNSForm 8.3 - US Solar Fund PLC
8th Dec 20221:47 pmRNSForm 8.3 - US Solar Fund PLC
8th Dec 20229:40 amRNSDirector/PDMR Shareholding
7th Dec 202210:48 amRNSForm 8.3 - US Solar Fund PLC
6th Dec 20223:16 pmRNSForm 8.3 - US Solar Fund PLC
2nd Dec 20221:46 pmRNSForm 8.3 - US Solar Fund PLC
1st Dec 20221:40 pmRNSForm 8.3 - US Solar Fund PLC
1st Dec 20227:00 amRNSTotal Voting Rights
24th Nov 20222:30 pmRNSForm 8.3 - US Solar Fund PLC
17th Nov 202210:14 amRNSForm 8.3 - US Solar Fund PLC
16th Nov 20221:43 pmRNSForm 8.3 - US Solar Fund PLC
10th Nov 202212:35 pmRNSForm 8.3 - US Solar Fund PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.